Table 3.

Analysis of variance models of plasma pexidartinib pharmacokinetic parameters

Pharmacokinetic parameter	Statistic	Esomeprazole study		Itraconazole study		Rifampin study		Probenecid study
		Pexidartinib alone	Pexidartinib + esomeprazole	Pexidartinib alone	Pexidartinib + itraconazole	Pexidartinib alone	Pexidartinib + rifampin	Pexidartinib alone	Pexidartinib + probenecid
Cmax, ng/mL	n	16	16	13	13	16	16	15	16
	Geometric LS mean	6431	2917	4255	6308	4924	3304	5034	5324
	Geometric LS mean ratio (%) (90% CI)	45.4 (36.8–55.9)		148.3 (127.8–172.0)		67.1 (53.1–84.8)		105.8 (92.4–121.0)
AUC∞, ng•h/mL	n	16	16	13	13	15	15	15	16
	Geometric LS mean	104,389	55,378	78,240	135,354	91,863	33,977	71,913	114,899
	Geometric LS mean ratio (%) (90% CI)	53.1 (47.4–59.3)		173.0 (160.7–186.3)		37.0 (30.6–44.8)		159.8 (143.4–178.0)

AUC_∞ area under the plasma concentration–time curve from 0 to infinity, CI confidence interval, C_max maximum plasma concentration, LS least square, SD standard deviation